In the test set, the median CPT1A level in breast cancer patients was 34.56 ± 42.31 ng/mL, which was notably higher than that of patients with benign breast disease (19.64 ± 12.33 ng/mL; p < 0.0001), or healthy controls (12.53 ± 11.43 ng/mL; Fig. 2b, p < 0.0001). Here, CPT1A is linked to breast cancer.